An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Inclusion Criteria

• •Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
• •Currently tolerating treatment in the parent protocol.
• •Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
• •Have at least stable disease, as determined by the investigator.
• •Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.